Johnson & Johnson (NYSE:JNJ) Stock Position Boosted by SevenBridge Financial Group LLC


Share on StockTwits

SevenBridge Financial Group LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 2.3% during the first quarter, HoldingsChannel.com reports. The fund owned 44,517 shares of the company’s stock after purchasing an additional 1,008 shares during the quarter. Johnson & Johnson makes up about 2.7% of SevenBridge Financial Group LLC’s portfolio, making the stock its 6th biggest holding. SevenBridge Financial Group LLC’s holdings in Johnson & Johnson were worth $7,316,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Cypress Point Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $25,000. Iron Horse Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $30,000. Joseph P. Lucia & Associates LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $32,000. Klaas Financial Asset Advisors LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $36,000. Finally, Interactive Financial Advisors purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $39,000. 67.25% of the stock is currently owned by institutional investors and hedge funds.

NYSE JNJ opened at $166.59 on Thursday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48. The company has a 50-day simple moving average of $161.05 and a 200-day simple moving average of $155.48. The firm has a market capitalization of $438.58 billion, a PE ratio of 26.19, a price-to-earnings-growth ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a one year low of $133.65 and a one year high of $173.65.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Monday, April 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.34 by $0.25. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company had revenue of $22.30 billion for the quarter, compared to the consensus estimate of $22 billion. During the same period in the previous year, the firm earned $2.30 EPS. Johnson & Johnson’s revenue was up 7.8% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 8th. Shareholders of record on Tuesday, May 25th will be given a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.55%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.01. The ex-dividend date of this dividend is Monday, May 24th. Johnson & Johnson’s payout ratio is 46.54%.

Several equities research analysts recently issued reports on JNJ shares. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $157.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 27th. SVB Leerink lifted their price target on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $180.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 26th. Finally, Cowen raised their price objective on shares of Johnson & Johnson from $170.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $180.29.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading: How to calculate compound interest

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.